{"url_path":"/sec/eltp/8-k/2026-06-01/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1053369/0001493152-26-026519-index.html","accession_number":"0001493152-26-026519","cik":"0001053369","ticker":"ELTP","issuer_name":"ELITE PHARMACEUTICALS INC /NV/","edgar_url":"https://www.sec.gov/Archives/edgar/data/1053369/0001493152-26-026519-index.html","primary_entity_key":"0001053369","primary_entity_name":"ELITE PHARMACEUTICALS INC /NV/"},"word_count":302,"has_tables":true,"body_markdown":"false\n0001053369\n\n0001053369\n\n2026-05-29\n2026-05-29\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n  \n\n \n\n \n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**WASHINGTON,\nD.C. 20549**\n\n \n\n**FORM\n8-K**\n\n \n\nCURRENT\nREPORT\n\n \n\nPURSUANT\nTO SECTION 13 OR 15(D)\n\nOF\nTHE SECURITIES EXCHANGE ACT OF 1934\n\n \n\nMay\n29, 2026\n\nDate\nof Report (Date of earliest event reported)\n\n \n\n**ELITE\nPHARMACEUTICALS INC /NV/**\n\n**ELITE\nPHARMACEUTICALS, INC.**\n\n(Exact\nname of registrant as specified in its charter)\n\n \n\nNevada\n \n001-15697\n\n22-3542636\n\n(State or other jurisdiction\n \n(Commission\n \n(IRS Employer\n\nof incorporation)\n \nFile Number)\n \nIdentification No.)\n\n \n\n165\nLudlow Avenue, Northvale, New Jersey 07647\n\n(Address\nof principal executive offices)\n\n \n\n(201)\n750-2646\n\n(Registrant’s\ntelephone number, including area code)\n\n \n\n \n\n \n\n(Former\nname or former address, if changed since last report.)\n\n \n\nCheck\nthe appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under\nany of the following provisions:\n\n \n\n☐\nWritten communications pursuant to Rule 425 under the\nSecurities Act (17 CFR 230.425)\n\n \n \n\n☐\nSoliciting material pursuant to Rule 14a-12 under the\nExchange Act (17 CFR 240.14a-12)\n\n \n \n\n☐\nPre-commencement communications pursuant to Rule 14d-2(b)\nunder the Exchange Act (17 CFR 240.14d-2(b))\n\n \n \n\n☐\nPre-commencement communications pursuant to Rule 13e-4(c)\nunder the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nIndicate\nby check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933\n(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging\ngrowth company ☐\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\n**Title\nof each class**\n \n**Trading\nSymbol(s)**\n \n**Name\nof each exchange on which registered**\n\nCommon Stock, par value\n$0.001 per share\n \nELTP\n \nOTCQB"}